Profile data is unavailable for this security.
About the company
Proteome Sciences plc is a specialist provider of contract proteomics services. The Company’s services enable drug discovery, development and biomarker identification, and employs proprietary workflows for the optimum analysis of tissues, cells and body fluids. Its principal activities involve protein biomarker research and development. It uses high-sensitivity techniques to detect and characterize differentially expressed proteins in biological samples for diagnostic, prognostic and therapeutic applications. SysQuant and TMT MS2 are unbiased methods for identifying and contextualizing new targets and defining mechanisms of biological activity, while analysis using Super-Depletion and TMTcalibrator provides access to over 8,500 circulating plasma proteins for the discovery of disease-related biomarkers. In addition, it has invented and developed the technology for TMT and TMTpro, and manufactures these small, protein-reactive chemical reagents for multiplex quantitative proteomics.
- Revenue in GBP (TTM)5.03m
- Net income in GBP-2.44m
- Incorporated1993
- Employees35.00
- LocationProteome Sciences PLCCoveham House, Downside Bridge RoadADDLESTONE KT11 3EPUnited KingdomGBR
- Phone+44 207 043 2116
- Fax+44 203 637 7516
- Websitehttps://www.proteomics.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Rua Life Sciences PLC | 1.87m | -1.87m | 6.83m | 40.00 | -- | 0.6535 | -- | 3.65 | -0.0843 | -0.0843 | 0.0843 | 0.1683 | 0.3293 | 3.26 | 4.80 | 46,725.00 | -32.95 | -25.97 | -36.33 | -28.26 | 81.97 | -- | -100.05 | -110.53 | 2.40 | -61.71 | 0.1065 | -- | 34.09 | 40.08 | 3.10 | -- | 94.82 | -- |
| Cambridge Nutritional Sciences PLC | 9.05m | -3.21m | 8.45m | 91.00 | -- | 0.908 | -- | 0.9338 | -0.0136 | -0.0105 | 0.0385 | 0.0391 | 0.5857 | 3.97 | 2.05 | 99,406.59 | -20.81 | -10.49 | -23.88 | -11.90 | 52.90 | 59.24 | -35.53 | -27.40 | 4.22 | -128.47 | 0.0225 | -- | -11.63 | -1.96 | -125.12 | -- | -45.83 | -- |
| Genedrive PLC | 272.00k | -5.00m | 9.10m | 43.00 | -- | 1.70 | -- | 33.45 | -0.0407 | -0.0407 | 0.0022 | 0.0098 | 0.0658 | -- | 1.60 | 6,325.58 | -120.84 | -97.55 | -197.86 | -128.51 | -- | -- | -1,837.50 | -797.03 | 1.36 | -7.49 | 0.0789 | -- | 12.24 | -50.95 | -10.16 | -- | 16.72 | -- |
| Feedback plc | 886.00k | -3.49m | 9.13m | 24.00 | -- | 1.02 | -- | 10.31 | -0.2614 | -0.2614 | 0.0664 | 0.6726 | 0.0774 | -- | 3.74 | 36,916.67 | -30.44 | -28.58 | -32.67 | -31.74 | 90.60 | 92.61 | -393.47 | -299.13 | -- | -- | 0.00 | -- | 74.15 | 17.46 | -37.74 | -- | 56.22 | -- |
| Proteome Sciences plc | 5.03m | -2.44m | 11.07m | 35.00 | -- | -- | -- | 2.20 | -0.0083 | -0.0083 | 0.017 | -0.0104 | 0.4209 | 3.89 | 3.04 | 143,657.10 | -20.45 | -1.22 | -- | -- | 32.76 | 54.53 | -48.59 | -2.20 | 0.2667 | -2.03 | 1.29 | -- | -35.37 | 10.52 | -284.38 | -- | 126.22 | -- |
| Inspiration Healthcare Group PLC | 37.63m | -6.32m | 11.94m | 210.00 | -- | 0.4122 | -- | 0.3173 | -0.0925 | -0.0925 | 0.5516 | 0.4245 | 0.7243 | 1.67 | 3.66 | -- | -12.17 | 0.8965 | -14.86 | 1.10 | 47.53 | 47.61 | -16.80 | 0.9922 | 0.9698 | -0.9172 | 0.307 | -- | -8.74 | 19.43 | -2,423.90 | -- | 31.88 | -- |
| Genincode PLC | 2.16m | -7.02m | 11.95m | 36.00 | -- | 5.02 | -- | 5.53 | -0.0732 | -0.0732 | 0.0225 | 0.0135 | 0.2703 | 21.88 | 3.33 | 60,000.00 | -87.79 | -- | -124.10 | -- | 47.31 | -- | -324.81 | -- | 1.24 | -- | 0.1883 | -- | 51.05 | -- | -26.21 | -- | -- | -- |
| Abingdon Health PLC | 5.34m | -2.24m | 12.99m | 82.00 | -- | 6.88 | -- | 2.43 | -0.0184 | -0.0184 | 0.0439 | 0.0149 | 0.8978 | 7.67 | 4.74 | 65,170.73 | -37.55 | -51.31 | -58.04 | -79.85 | 57.35 | 33.16 | -41.82 | -139.64 | 1.59 | -- | 0.3572 | -- | 42.68 | -- | 83.77 | -- | -- | -- |
| Verici DX PLC | 795.13k | -6.86m | 15.77m | 14.00 | -- | 3.96 | -- | 19.83 | -0.0403 | -0.0403 | 0.0047 | 0.0164 | 0.0932 | -- | 1.59 | 56,795.29 | -80.32 | -- | -115.94 | -- | 1.58 | -- | -862.19 | -- | -- | -- | 0.0438 | -- | -- | -- | 23.43 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| Vulpes Investment Management Pte Ltd.as of 13 Apr 2023 | 67.79m | 22.97% |
| Hargreaves Lansdown Asset Management Ltd.as of 01 Jun 2024 | 13.67m | 4.63% |
| Jarvis Investment Management Ltd.as of 01 Jun 2024 | 8.92m | 3.02% |
| James Brearley & Sons Ltd.as of 01 Jun 2024 | 3.33m | 1.13% |
| ISPartners Investment Solutions AGas of 01 Jun 2024 | 2.24m | 0.76% |
| Rowan Dartington & Co. Ltd. (Broker)as of 01 Jun 2024 | 2.20m | 0.75% |
| Walker Crips Investment Management Ltd.as of 01 Jun 2024 | 1.79m | 0.61% |
| IG Markets Ltd.as of 01 Jun 2024 | 1.41m | 0.48% |
| J. M. Finn & Co. Ltd.as of 01 Jun 2024 | 790.00k | 0.27% |
| HSBC Global Asset Management (UK) Ltd.as of 01 Jun 2024 | 646.00k | 0.22% |
